Artivion (AORT) vs Beta Bionics (BBNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Beta Bionics (BBNX) has outperformed Artivion (AORT) over the past year, losing 57.5% versus a loss of 59.8%. Artivion is the larger company by market cap ($886.0 million vs $726.3 million), about 1.2 times the size, while Beta Bionics is growing revenue faster (+53.9% vs +13.6%). Artivion converts more of its revenue into profit, with a net margin of 2.2% versus -73.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AORT | BBNX |
|---|---|---|
| Share price | $18.16 | $13.36 |
| Market cap | $886.02M | $726.34M |
| 1-day change | -2.00% | +0.30% |
| YTD return | -60.18% | -56.15% |
| 1-year return | -59.76% | -57.48% |
| 5-year return | -0.82% | — |
| Forward P/E | 34.92 | — |
| EPS (TTM) | $-0.36 | $-1.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $441.33M | $100.25M |
| Revenue growth (YoY) | +13.59% | +53.94% |
| Net income (latest FY) | $9.77M | $-73.20M |
| Gross margin | 64.40% | 55.40% |
| Operating margin | 7.65% | -71.50% |
| Net margin | 2.21% | -73.02% |
| 52-week high | $48.25 | $32.71 |
| 52-week low | $18.12 | $8.80 |
| Distance from 52-week high | -62.36% | -59.16% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +111.84% | +87.87% |
| Average volume | 671.97K | 1.21M |
| Shares outstanding | 48.79M | 54.37M |
| Employees | 1,800 | 420 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Artivion is more profitable, keeping 2.2 cents of every revenue dollar as net income versus -73.0 cents for Beta Bionics.
- Beta Bionics grew revenue faster in its latest fiscal year (+53.94% vs +13.59%).
About Artivion
AORT stock →Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide.
Health Care · Medical/Dental Instruments · 1,800 employees
About Beta Bionics
BBNX stock →Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older.
Health Care · Medical/Dental Instruments · 420 employees
AORT vs BBNX FAQ
Which is bigger, Artivion or Beta Bionics?
Artivion (AORT) is larger, with a market capitalization of $886.02M compared with $726.34M for Beta Bionics (BBNX).
Which stock has performed better over the past year, AORT or BBNX?
BBNX returned -57.48% over the past 12 months, compared with -59.76% for AORT (price return, excluding dividends). Past performance does not predict future results.
Are Artivion and Beta Bionics in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.